A novel bionic vesicle is developed by Professor Jianqing Gao from CPS-ZJU, and Researcher Pengxu Qian from School of Medicine, Liangzhu Laboratory. HSPC liposomes are constructed by combining the membranes of hematopoietic stem cells and progenitor cells (HSPC) with liposomes, which are used to deliver chemotherapy drugs to bone marrow foci. To achieve an effective treatment for leukemia, the study was published in the July 2024 issue of Nature Communications. The bionic vesicles were able to reside efficiently in the bone marrow of mice with leukemia via the hyaluronic acid-CD44 axis. Through the interaction of intercellular adhesion molecule-1 (ICAM-1) and integrin β2 (ITGB2), it showed superior binding affinity to leukemia cells. Further experiments demonstrated that the vesicles carrying the chemotherapeutic drug cytarabine (Ara-C@HSPC-Lipo) could significantly inhibit the proliferation of leukemia cells, induce apoptosis and differentiation, and reduce the number of leukemia stem cells. Using RNA sequencing analysis, the researchers found that Ara-C@HSPC-Lipo treatment induced apoptosis and differentiation, and inhibited the carcinogenic pathway. Finally, the study also confirmed the safety of HSPC liposomes in mice.